SAROJA — Saroja Pharma Industries India Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapValue Trap

Annual income statement for Saroja Pharma Industries India, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	367	556	502	407	537
Cost of Revenue
Gross Profit	33.2	53.1	49	50.3	51.5
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	354	536	475	382	511
Operating Profit	12.8	20.6	26.5	24.6	26.7
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	10.4	15.8	14.9	12.1	14.5
Provision for Income Taxes
Net Income After Taxes	7.31	11.4	10.6	8.78	10.3
Net Income Before Extraordinary Items
Net Income	7.31	11.4	10.6	8.78	10.3
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	7.31	11.4	10.6	8.78	10.3
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.82	2.84	2.64	2.49	2.57
Dividends per Share